AstraZeneca, Daiichi Sankyo enter into co-promotion agreement
AstraZeneca has announced the formation of a co-promotion agreement in Japan with Daiichi Sankyo to co-promote denosumab for treating bone disorders that stem from bone metastasis. Once the treatment is approved in Japan, the two companies will co-promote it. Daiichi Sankyo acquired rights to denosumab in Japan in 2007 from Amgen Inc. and filed a Japanese New Drug Application in August 2010.
Denosumab, with its novel mode of action and targeted delivery via a monthly subcutaneous injection, represents a new treatment option in Japan for the management of bone metastasis across a broad range of cancer types.
Bone metastasis takes place when cancer cells from the primary tumor relocate to a patient's bone, can lead to bone fractures and is one of the most frequent causes of pain for cancer patients. Denosumab is the first approved therapy that targets RANK Ligand, which regulates osteoclasts, the cells that break down bone. By targeting this regulator, denosumab has been proven to prevent the spread of cancer to the bone. The treatment is delivered as a monthly subcutaneous injection.
"Collaborations like this are a key part of our strategy to bring innovative medicines to patients," says Tony Zook, Executive Vice President of AstraZeneca's Global Commercial Organization. "This partnership leverages our long-standing commitment to oncology in Japan, and we look forward to contributing our expertise in this area to bring this novel cancer treatment to patients upon approval."
Financial details of the agreement were not disclosed.